At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
89Zr-TLX250drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating 89Zr-TLX250 for Triple Negative Breast Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer
CountriesFrance
CollaboratorsTarix Pharmaceuticals, SIRIC ILIAD
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartSep 2021
Primary CompletionMar 2023
Study CompletionSep 2023
TodayJul 2026
First PostedFeb 17, 2021
Enrollment StartSep 21, 2021
Primary CompletionMar 31, 2023
Study CompletionSep 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.4 years ago
Interventions
89Zr-TLX250drug
89Zr-TLX250 PET/CT